Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Non-Current Assets for 10 consecutive years, with $227.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 5.55% year-over-year to $227.5 million; the trailing twelve-month figure through Jun 2026 stood at $931.8 million (down 4.62% YoY), and the FY2025 full-year result was $236.5 million, down 4.94% from the prior year.
• Non-Current Assets fell to $227.5 million in Q2 2026 per KNSA's latest filing, from $231.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $250.0 million in Q4 2023 and bottomed at $30.6 million in Q2 2022.
• Historically, Non-Current Assets has averaged $212.4 million across 5 years, with a median of $236.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets decreased 10.93% in 2022, then jumped 677.77% in 2023.
• Over 5 years, Non-Current Assets stood at $216.6 million in 2022, then gained by 15.43% to $250.0 million in 2023, then slipped by 0.51% to $248.8 million in 2024, then slipped by 4.94% to $236.5 million in 2025, then fell by 3.8% to $227.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $227.5 million, $231.1 million, and $236.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.